Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy

Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy

Diffuse large cell B cell lymphoma (DLBCL) accounts for approximately 30%–40% of all non-Hodgkin lymphoma (NHL) cases. Current first line DLBCL treatment results in long-term remission in more than 60% of cases. However, those patients with primary refractory disease or early relapse exhibit poor pr...

Full description

Bibliographic Details
Main Authors: Russell Foxall, Priyanka Narang, Bridget Glaysher, Elin Hub, Emma Teal, Mark C. Coles, Margaret Ashton-Key, Stephen A. Beers, Mark S. Cragg
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
diffuse large B cell lymphoma
antibody therapy
adipocyte derived stem cell
cancer associated fibroblast
tumor associated macrophage
3D co-culture model
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.605231/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.605231/full

Similar Items